Central nervous system infections - A potential complication of systemic immunotherapy

Bernhard Hemmer, Elliot Frohman, Hans Peter Hartung, Olaf Stuve

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose of review: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage. With the emergence of more efficient immune therapies, severe sometimes even fatal central nervous system infections were observed. This review will address the role of the systemic immune system in central nervous system immune surveillance and discuss implications for the development of novel immunotherapies in multiple sclerosis. Recent findings: In the last decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treatment of multiple sclerosis, based on the results of double-blind placebo-controlled randomized clinical trials. A better understanding of the pathogenesis of the disease has prompted exploration of the therapeutic utility of new drugs that more potently disrupt the pathophysiological cascade of events that culminates in central nervous system tissue damage. One potential side-effect of these newer therapies is their interference with the control of central nervous system infections by the immune system. Summary: Any increase in potency of multiple sclerosis therapies could well interfere with protective immunosurveillance of the central nervous system. One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future.

Original languageEnglish (US)
Pages (from-to)271-276
Number of pages6
JournalCurrent Opinion in Neurology
Volume19
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Central Nervous System Infections
Immunotherapy
Multiple Sclerosis
Central Nervous System
Immune System
Therapeutics
Immunologic Monitoring
Nerve Tissue
Opportunistic Infections
Demyelinating Diseases
Immunosuppressive Agents
Immunosuppression
Chronic Disease
Randomized Controlled Trials
Placebos
Incidence
Pharmaceutical Preparations

Keywords

  • Central nervous system immune surveillance
  • Immunosuppression
  • Immunotherapy
  • Multiple sclerosis
  • Natalizumab
  • Tysabri

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Central nervous system infections - A potential complication of systemic immunotherapy. / Hemmer, Bernhard; Frohman, Elliot; Hartung, Hans Peter; Stuve, Olaf.

In: Current Opinion in Neurology, Vol. 19, No. 3, 06.2006, p. 271-276.

Research output: Contribution to journalArticle

@article{3ef6ce352c82412ba64f38555bfbc925,
title = "Central nervous system infections - A potential complication of systemic immunotherapy",
abstract = "Purpose of review: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage. With the emergence of more efficient immune therapies, severe sometimes even fatal central nervous system infections were observed. This review will address the role of the systemic immune system in central nervous system immune surveillance and discuss implications for the development of novel immunotherapies in multiple sclerosis. Recent findings: In the last decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treatment of multiple sclerosis, based on the results of double-blind placebo-controlled randomized clinical trials. A better understanding of the pathogenesis of the disease has prompted exploration of the therapeutic utility of new drugs that more potently disrupt the pathophysiological cascade of events that culminates in central nervous system tissue damage. One potential side-effect of these newer therapies is their interference with the control of central nervous system infections by the immune system. Summary: Any increase in potency of multiple sclerosis therapies could well interfere with protective immunosurveillance of the central nervous system. One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future.",
keywords = "Central nervous system immune surveillance, Immunosuppression, Immunotherapy, Multiple sclerosis, Natalizumab, Tysabri",
author = "Bernhard Hemmer and Elliot Frohman and Hartung, {Hans Peter} and Olaf Stuve",
year = "2006",
month = "6",
doi = "10.1097/01.wco.0000227037.70329.b0",
language = "English (US)",
volume = "19",
pages = "271--276",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Central nervous system infections - A potential complication of systemic immunotherapy

AU - Hemmer, Bernhard

AU - Frohman, Elliot

AU - Hartung, Hans Peter

AU - Stuve, Olaf

PY - 2006/6

Y1 - 2006/6

N2 - Purpose of review: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage. With the emergence of more efficient immune therapies, severe sometimes even fatal central nervous system infections were observed. This review will address the role of the systemic immune system in central nervous system immune surveillance and discuss implications for the development of novel immunotherapies in multiple sclerosis. Recent findings: In the last decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treatment of multiple sclerosis, based on the results of double-blind placebo-controlled randomized clinical trials. A better understanding of the pathogenesis of the disease has prompted exploration of the therapeutic utility of new drugs that more potently disrupt the pathophysiological cascade of events that culminates in central nervous system tissue damage. One potential side-effect of these newer therapies is their interference with the control of central nervous system infections by the immune system. Summary: Any increase in potency of multiple sclerosis therapies could well interfere with protective immunosurveillance of the central nervous system. One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future.

AB - Purpose of review: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage. With the emergence of more efficient immune therapies, severe sometimes even fatal central nervous system infections were observed. This review will address the role of the systemic immune system in central nervous system immune surveillance and discuss implications for the development of novel immunotherapies in multiple sclerosis. Recent findings: In the last decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treatment of multiple sclerosis, based on the results of double-blind placebo-controlled randomized clinical trials. A better understanding of the pathogenesis of the disease has prompted exploration of the therapeutic utility of new drugs that more potently disrupt the pathophysiological cascade of events that culminates in central nervous system tissue damage. One potential side-effect of these newer therapies is their interference with the control of central nervous system infections by the immune system. Summary: Any increase in potency of multiple sclerosis therapies could well interfere with protective immunosurveillance of the central nervous system. One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future.

KW - Central nervous system immune surveillance

KW - Immunosuppression

KW - Immunotherapy

KW - Multiple sclerosis

KW - Natalizumab

KW - Tysabri

UR - http://www.scopus.com/inward/record.url?scp=33744487388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744487388&partnerID=8YFLogxK

U2 - 10.1097/01.wco.0000227037.70329.b0

DO - 10.1097/01.wco.0000227037.70329.b0

M3 - Article

C2 - 16702834

AN - SCOPUS:33744487388

VL - 19

SP - 271

EP - 276

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 3

ER -